Skip to main content
OpenTrials
Completed

NCT Number: NCT03446625

Resveratrol as a Preventive Treatment of OHSS

Evaluation of resveratrol treatment oh ovarian hyperstimulation syndrome in egg donors

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

18 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Ivi Madrid

Madrid, 28023, Spain

About this study

Randomized clinical trial to evaluate the role of resveratrol in preventing ovarian hyperstimulation syndrome by reducing VGEF expression and estradiol production, imporving hemoconcentration and symptomathology of this condition

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Number of follicles greater than 12 mm after ovarian stimulation
  • Number of retrieved oocytes greater than 21

Exclusion criteria

  • >35 years-old
  • PCOS
  • Endometriosis
  • Systemic pathology
  • Positive serologies for HBV, HBC and HIV
  • Abnormal karyotype

Treatment and study plan

Resveratrol

Drug

Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.

Other names: Resverasor Plus

Placebo

Drug

Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.

Primary outcomes

  1. Serum VEGF levels

    Time frame: 1 day

    Serum determination of VEGF levels

Secondary outcomes

  1. Hemoconcentration

    Time frame: 1 day

    Volume of red blood cells measured in percentage

  2. Serum estradiol levels

    Time frame: 1 day

    Serum determination of estradiol levels asessed in picograms per mililiter

  3. Ascitis

    Time frame: 1 day

    Volume of liquid in Douglas pouch asessed in mililiters

Sponsors and collaborators

Lead sponsor

IVI Madrid

Other

Registry information

Official study title

Resveratrol as a Preventive Treatment of Ovarian Hyperstimulation Syndrome

Acronym: RES-OHSS

Important dates

Study start
2018
Primary completion
2018
Study completion
2019
First posted
Feb 27, 2018
Registry last updated
Aug 20, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.